Medtronic PLC

NYSE MDT

Download Data

Medtronic PLC Price to Earnings Ratio (P/E) on June 03, 2024: 64.14

Medtronic PLC Price to Earnings Ratio (P/E) is 64.14 on June 03, 2024, a 116.49% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • Medtronic PLC 52-week high Price to Earnings Ratio (P/E) is 67.49 on May 17, 2024, which is 5.21% above the current Price to Earnings Ratio (P/E).
  • Medtronic PLC 52-week low Price to Earnings Ratio (P/E) is 25.52 on October 27, 2023, which is -60.22% below the current Price to Earnings Ratio (P/E).
  • Medtronic PLC average Price to Earnings Ratio (P/E) for the last 52 weeks is 33.56.
NYSE: MDT

Medtronic PLC

CEO Mr. Geoffrey Straub Martha
IPO Date Jan. 13, 1978
Location Ireland
Headquarters 20 On Hatch, Dublin, Ireland, 2
Employees 95,000
Sector Healthcare
Industry Medical devices
Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Similar companies

ABT

Abbott Laboratories

USD 102.87

0.67%

StockViz Staff

September 8, 2024

Any question? Send us an email